Fig 1: Validation of the 5 candidate proteins (KRT1, APOB, FN1, SERPINC1 and SERPINA1) by ELISA in the control children, and -Treatment and +Treatment patients. The control group is shown in gray, the -Treatment in blue and the +Treatment in brown. Data are expressed as mean ± standard deviation (n=25 biological replicates in each group). The multiple comparisons test of control vs. -Treatment and control vs. +Treatment are performed using ANOVA with Dunnett or Welch with Dunnett's T3 test based on the result of variance homogeneity. Except for KRT1 (ANOVA statistics), the variances of APOB, FN1, SERPINC1 and SERPINA1 were not homogenous. ?Data were analyzed using a Welch test. *P<0.05 and ***P<0.001 vs. control. KRT1, keratin 1; APOB, apolipoprotein B; FN1, fibronectin 1; SERPINC1, antithrombin III; SERPINA1, a-1-antitrypsin; ANOVA, analysis of variance.
Fig 2: Validation of proteomics results by western blot analysis. (A) Western blot analysis was used for the validation of 5 proteins (KRT1, APOB, FN1, SERPINC1 and SERPINA1) from control, -Treatment and +Treatment samples; ß-actin was used as an internal control. (B) Histogram of western blot analysis. The control group is shown in gray, the -Treatment group is blue and the +Treatment group is brown. Data are expressed as mean ± standard deviation (n=25 biological replicates in each group). The multiple comparisons test of control vs. -Treatment and control vs. +Treatment are performed using analysis of variance with Dunnett's test. *P<0.05, **P<0.01 and ***P<0.001 vs. control. KRT1, keratin 1; APOB, apolipoprotein B; FN1, fibronectin 1; SERPINC1, antithrombin III; SERPINA1, a-1-antitrypsin.
Supplier Page from Abnova Corporation for APOB (Human) ELISA Kit